With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
AME — frequently asked questions
Is AMETEK Inc. overvalued?
In our latest published analysis dated 2026-10-04, AME looks meaningfully overvalued. The price recorded at analysis is USD 252 versus our fair value of USD 172; the high endpoint is presented separately as potential value of USD 196. That implies roughly 31.8% downside to fair value at that date.
Our latest published report, analyzed 2026-10-04, gives AME a fair value of USD 172 and a potential value of USD 196. The conclusion is triangulated across multiple valuation models and weighted by reliability for AMETEK Inc.'s archetype; it is a dated research output, not a live price.
Should I buy AME now?
Our latest published rating for AME, analyzed 2026-10-04, is Sell. AMETEK Inc. looks meaningfully overvalued at the analysis-date price of USD 252 versus fair value of USD 172; potential value is USD 196. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for AME?
The dedicated bear-case section in our report analyzed 2026-10-04 documents AMETEK Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is AME's rating?
Our latest published rating for AME, analyzed 2026-10-04, is Sell, with a published moat assessment of 9/10 (Wide). It reflects our fair value of USD 172, the potential value of USD 196, and the price recorded at analysis (USD 252).
Accelerated margin accretion and recurring revenue scaling from the $5.0B Indicor Instrumentation acquisition, which adds approximately $350M in 2026 sales and expands high-margin consumables and software to 50% of acquired revenue, combined with secular aerospace and semiconductor demand driving FY2027 diluted EPS toward $9.90.
Main risk
Severe synchronized global industrial downturn contracting European and Asian organic revenue growth below -5% YoY.
AMETEK Inc. is rated Sell with a committee fair value of $171.80 per share, indicating an implied return of -31.8% from the October 2, 2026 share price of $251.93. While AMETEK demonstrates exceptional operating discipline with FY2025 operating margins of 25.81% and 113% free cash flow conversion, trading at 28.25x forward earnings imposes an extreme 46.6% premium over intrinsic value that leaves investors unprotected against cyclical slowdowns and multiple compression.4,6,7
Valuation disconnect drives our Sell rating. AMETEK currently trades at $251.93 per share, representing a forward P/E multiple of 28.25x. This valuation stands substantially above peer multiples such as Cummins at 15.28x, Generac at 17.43x, and the peer forward P/E median of 19.83x. At current levels, the market prices in uninterrupted double-digit expansion and aggressive terminal multiple sustainability, resulting in an implied return of -31.8%.3,4
Bear-case scrutiny identifies substantial cyclical and integration risks. Geographically, European Union revenue ($1,089,530,000) and Asian revenue ($1,488,788,000) represent 34.8% of consolidated FY2025 sales ($7,401,116,000). A synchronized industrial downturn across European discrete manufacturing and Asian electronics markets would push organic revenue growth below -5% YoY, triggering an estimated -28.5% intrinsic valuation contraction. Concurrently, absorbing the $5.0B cash acquisition of Indicor Instrumentation increases funded debt well above the reported $2,310,944,000 and expanded the commercial paper program to $3.5B. Unanticipated integration friction compressing consolidated operating margins toward 22.8% would drive an additional -22% fair value impairment.4,5,7,8
Operational execution remains elite, but high quality cannot justify an arbitrary price. In FY2025, AMETEK generated $1,910,317,000 in operating income (25.81% margin), driven by EIG generating $1,447,057,000 on $4,919,100,000 sales and EMG delivering $578,938,000 on $2,482,016,000 sales. Free cash flow reached $1,671,515,000 on capital expenditures of only $130,248,000, confirming superior capital efficiency. Nonetheless, disciplined investing requires separating business quality from share price. Trading at a 46.6% premium to fair value with a computed WACC of 9.0619%, risk is heavily skewed to the downside, supporting an unequivocal Sell rating.2,6,7,8
AMETEK manufactures mission-critical, customized instrumentation deployed in regulatory-driven, high-consequence environments where customer switching costs are high. This structural advantage enabled the company to offset input inflation and tariffs with positive net pricing while sustaining a 25.81% operating margin on $1,910.32M EBIT in FY2025.5,7
Operating cash flow was $1,801.76M in FY2025 against capital expenditures of only $130.25M (~2% of sales), generating $1,671.52M in . Converting 113% of ($1,480.14M) into cash allows programmatic reinvestment without external dilutive equity financing.
House recommendation
Sell. AMETEK is an operationally elite industrial compounder with robust 25.81% operating margins and 113% free cash flow conversion, but its stock is significantly overextended at $251.93 (28.25x forward earnings). With our committee mid fair value set at $171.80, implying -31.8% downside return, valuation risk heavily outweighs compounding fundamentals.4,6,7
Company overview
AMETEK, Inc. is a leading global manufacturer of industrial technology solutions, electronic instruments, and electromechanical devices headquartered in Berwyn, Pennsylvania. The company operates through two primary reporting segments: Electronic Instruments Group (EIG) and Electromechanical Group (EMG). In FY2025, consolidated net sales reached $7,401,116,000, expanding from $5,546,514,000 reported in FY2021.
EIG designs and manufactures advanced analytical, test, and measurement instrumentation for process, aerospace, power, and industrial research applications, generating $4,919,100,000 in FY2025 revenue (66.5% of net sales) and $1,447,057,000 in operating income. EMG produces highly engineered electrical interconnects, precision motion control systems, medical components, and specialty metals, delivering $2,482,016,000 in FY2025 revenue and $578,938,000 in operating income. Corporate administrative expenses were $115,678,000 in FY2025, yielding consolidated operating income of $1,910,317,000.
In a comprehensive stress test combining an industrial downturn with M&A execution friction, AMETEK faces simultaneous compression across revenue, margins, and valuation multiples. A synchronized slowdown in European manufacturing ($1,089.53M EU sales) and Asian factory automation ($1,488.79M Asia sales) reduces consolidated organic revenue by 5%. Simultaneously, unanticipated integration complexities and unrecovered tariff costs from the $5.0B Indicor transaction compress operating margins from 25.81% to 22.8%. With short-term commercial paper expanded to $3.5B to fund the purchase, higher floating interest rates elevate pre-tax debt costs above 5.78%, driving WACC toward 11.06%. Under these combined pressures, the market multiple re-rates sharply downward from 28.25x forward earnings toward the peer median of 19.8x (anchored by CMI at 15.28x and GNRC at 17.43x), driving valuation down to the committee lower bound of $150.89.
AMETEK commands a wide competitive moat established across decades of focused leadership in mission-critical niche instrumentation and specialized electromechanical components. The company operates through two core segments: the Electronic Instruments Group (EIG), which generated $4,919.10M in revenue and $1,447.06M in operating income in FY2025, and the Electromechanical Group (EMG), which generated $2,482.02M in revenue and $578.94M in operating income. These businesses design custom, highly engineered hardware and software that operate in harsh, tightly regulated environments such as aerospace cockpits, semiconductor fabrication chambers, medical devices, and industrial processing plants. Because failure in these systems causes catastrophic operational disruptions or regulatory violations, customers face prohibitive switching costs and maintain long qualification cycles, insulating AMETEK from commodity price competition.
The structural foundation of AMETEK's pricing power rests on low obsolescence risk and deep technical customization. In long-cycle platforms across aerospace and power infrastructure, AMETEK's products are specified directly into OEM master blueprints. This dynamic allows the company to consistently implement price increases that fully offset input inflation and import tariffs, as demonstrated in Q2 2026 where price realization exceeded tariff and inflationary headwinds. Moreover, the AMETEK Growth Model combines operational excellence with programmatic, value-accretive M&A. The August 2026 completion of the $5.0B Indicor Instrumentation acquisition further expands this by adding complementary niche technologies with a highly profitable 50% recurring base from consumables and service agreements.
The highlighted cell is Fair value when every assumption sits at its base level ($171.80). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.5B after modeled reinvestment of $267.6M, with terminal value at 78.1% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Upgrade to Reduce; Maintain capital discipline and use any post-earnings liquidity surge to systematically complete the divestment program, re-examining whether Indicor integration pace justifies adjusting long-term terminal growth assumptions.
Trigger: Adjusted diluted EPS and organic revenue growth exceeding consensus guidance in Q3 and full-year FY2026 driven by outperforming aerospace and semiconductor shipments.
A quarterly operational beat driven by aerospace and semiconductor momentum validates business quality but does not eliminate the substantial valuation premium over fair value, justifying an upgrade stance rather than a constructive posture.
In-line
Maintain Sell; Continue orderly position liquidation, monitoring book-to-bill metrics and commercial paper borrowing costs for early signs of margin or interest expense pressure.
Industry capex-to-revenue stands at 4.1% and industry capex-to-depreciation at 0.68, demonstrating that the broader capital equipment sector remains disciplined and is not engaging in destructive greenfield capacity overbuilding. AMETEK operates with an even more asset-light footprint: FY2025 CapEx was $130.25M on $7,401.12M revenue (1.76% of sales), and FY2026 CapEx is guided to approximately $160M (~2.0% of sales). Management explicitly confirmed that operations are not at capacity limits, having added modular footprint in Serbia, Mexico, and Poland without heavy fixed capital deployment.5
Bull cycle
The bullish industrial cycle is propelled by accelerating global infrastructure investments, extensive electrical power grid build-outs, and robust commercial aerospace production ramp-ups. In this phase, customer demand for high-precision analytical instrumentation and mission-critical components outstrips baseline manufacturing capacity, driving book-to-bill ratios above 1.12 and accelerating backlog growth past $4.11B. High capacity utilization among semiconductor fabs and medical device OEMs enables rapid absorption of price increases, allowing specialized suppliers to expand gross margins beyond 37.5% while compounding organic at high-single to double-digit rates.
§11 Position management
Sizing
0%
Given the committee Sell rating and the significant valuation gap where the October 2, 2026 share price ($251.93) trades at a 46.64% premium over mid fair value ($171.80) and an implied return of -31.81%, institutional and retail portfolios should maintain zero long allocation. Complete divestment preserves capital against multiple contraction toward peer norms.4
Risk
Portfolio risk management dictates absolute avoidance of unhedged equity exposure to AMETEK at current extended valuation multiples. Trading at a 46.64% premium to intrinsic midpoint fair value ($171.80), the stock presents severe downside vulnerability to multiple contraction. Institutional portfolios holding mandated benchmark weights should implement equity collar structures, purchasing out-of-the-money put options funded by selling calls, or rotate capital into diversified industrials trading at reasonable multiples (such as Cummins at 15.28x forward P/E). Credit risks associated with the newly expanded $3.5B commercial paper program used to fund the $5.0B Indicor transaction must be monitored closely, as floating rate resets could elevate annual interest burden above current historical levels ($30.10M in Q2 2026).
§12 Investor perspectives
Institutional Value Mandates
Avoid
At $251.93, AME trades at a 46.6% premium to the committee mid fair value of $171.80 and a forward P/E of 28.25x. With an implied return of -31.8%, margin of safety is nonexistent, making the shares uninvestable for value-disciplined portfolios.4
Quality Compounder Allocators
Avoid
Although AMETEK demonstrates benchmark operational execution with 25.81% operating margins and 113% FCF conversion, acquiring quality compounders at excessive multiples compromises long-term returns.6,7
§14 Final recommendation
Action
Sell
We assign a Sell rating to AMETEK Inc. with a committee fair value of $171.80 per share. The October 2, 2026 share price of $251.93 reflects an unsustainable valuation premium of 46.6% over intrinsic fair value (-31.8% implied return), pricing in flawless integration of the Indicor acquisition and perpetual high-teens multiples.4,5
While AMETEK remains an elite compounder with 25.81% operating margins and 113% free cash flow conversion, trading at 28.25x forward earnings versus peer medians of 19.83x exposes shareholders to severe multiple contraction if industrial momentum decelerates.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-04 · Published 2026-10-04 · Provider-adjusted · cited for 1 figureCited in Final recommendation
Secular Growth in EIG and Recurring Revenue Scaling
Electronic Instruments Group generated $4,919.10M in net sales and $1,447.06M in operating profit in FY2025, benefiting from secular tailwinds in aerospace, power grid build-out, and semiconductor equipment. The $5.0B Indicor Instrumentation acquisition strengthens this platform by adding high-margin recurring consumables and software revenue streams.5,8
Geographically, AMETEK serves a diverse customer base across the United States and international markets. In FY2025, United States sales were $3,830,639,000, while international revenue totaled $3,570,477,000. Regional international contributions included $1,488,788,000 from Asia, $1,089,530,000 from the European Union, $730,226,000 from other foreign territories, and $261,933,000 from the United Kingdom.
Organic revenue growth decelerates into contraction territory YoY as European manufacturing and Asian electronics demand remains depressed.
Consolidated operating margins compress meaningfully from FY2025 levels due to unabsorbed fixed costs, restructuring charges, and tariff pass-through lags.
Diluted EPS growth decelerates markedly across the projection horizon.
Weighted average cost of capital elevates as floating-rate debt spreads widen post-Indicor acquisition.
Forward valuation multiple contracts toward diversified peer median levels.
The bear case models severe macroeconomic headwinds where prolonged industrial contraction in Europe and Asia undermines organic volume growth, while unforeseen Indicor integration friction and unrecovered tariff inflation depress operating margins. Elevated debt service costs from commercial paper borrowings increase capital costs, while decelerating earnings momentum triggers valuation de-rating toward lower-quartile diversified industrial peer levels.
Ways this thesis can break
Severe global industrial downturn contracting European and Asian demand
Europe generated $1,089.53M and Asia generated $1,488.79M in FY2025, accounting for 34.8% of consolidated net sales ($7,401.12M). A synchronized slump across European machinery and Asian electronics that drives organic revenue growth below -5% YoY would contract consolidated sales and lead to an estimated -28.5% fair value decline.7,8
FV impact
-3%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 12 months
Indicor integration friction and tariff cost pressure compressing operating margins
Consolidated GAAP operating margin reached 25.81% in FY2025 on $1,910.32M EBIT. Unanticipated integration friction, restructuring costs, and inability to offset input tariffs across acquired Indicor product lines compressing operating margins below 22.8% of revenue would cause an estimated -22.0% fair value impact.5,7
FV impact
-0.9%
Operating margin 3 points lower throughout
Trigger
Within 18 months
Higher refinancing cost and leverage-driven cost of capital shock
AMETEK's computed WACC is 9.0619% with a 5.24% risk-free rate. Funding the $5.0B Indicor transaction expands debt well above reported $2,310.94M and relies on an expanded $3.5B commercial paper program. A 200 bps increase in cost of capital to 11.06% driven by floating-rate refinancing and credit spread widening impairs intrinsic value by -19.5%.2,4
FV impact
-18.8%
Cost of capital 2 points higher
Trigger
Within 24 months
Equity multiple de-rating toward industrial peer median
AMETEK currently trades at 28.25x forward earnings, a substantial premium to peers CMI (15.28x) and GNRC (17.43x). Slower post-acquisition organic growth and broader sector multiple contraction compressing forward P/E below 19.8x drives an estimated -24.0% fair value impairment.3,4
FV impact
-4.9%
Terminal multiple 20% lower
Trigger
Within 12 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
01
Organic Sales Growth Rate
Signals that cyclical slowdowns in European machinery and Asian consumer electronics are overwhelming niche pricing power, directly undermining the organic compounding premise.
Indicates that debt financing for the $5.0B Indicor transaction, executed via commercial paper expanded to $3.5B, leaves the capital structure exposed to floating-rate spikes and refinancing shocks.
Demonstrates that customer project deferrals and order cancellations across process and automation markets are outpacing shipments, signaling future revenue contraction.
Despite these structural advantages, the moat is not immune to cyclical and integration risks. While AMETEK's asset-light manufacturing footprint (maintaining CapEx at ~2% of sales) enables rapid free cash flow conversion of 111%, organic volume remains dependent on capital expenditure cycles across international manufacturing hubs. With international markets contributing $3,570.48M (48.24%) of FY2025 sales, synchronous weakness in European machinery or Asian electronics can erode operating leverage before cost reductions take effect. Nonetheless, the high cost of substitution and fragmented competitive landscapes in its target niches ensure that AMETEK's economic returns remain durable across the cycle.
AMETEK generates outstanding economic profit well above industry norms. In FY2025, the company delivered GAAP operating income of $1,910.32M on revenue of $7,401.12M, achieving a 25.81% operating margin, nearly 1,000 basis points above the peer industry operating margin of 16.1%. With an asset-light operating model requiring only $130.25M of CapEx in FY2025 (1.76% of sales) and ~$160M guided for FY2026 (~2% of sales), AMETEK generates a return on invested capital of 11.73% that consistently exceeds its computed WACC of 9.0619%.2,5,7
9/ 10
Wide
Sources of advantage
01High Switching Costs & Embedded Mission-Critical Specifications — AMETEK manufactures specialized instrumentation specified into regulated aerospace, medical, and process applications where the high price of failure creates substantial switching barriers, allowing the company to pass through tariff and material cost inflation while maintaining low platform obsolescence risk.Wide
02Proprietary Intellectual Property & Niche Domain Expertise — The company holds differentiated technologies and strong IP portfolios across specialized measurement, thermal management, and precision automation, bolstered by the Indicor acquisition which brings a 50% profitable recurring revenue stream from consumables and software.Wide
03Platform Scale & Serial M&A Operating Integration — The disciplined AMETEK Growth Model systematically acquires leading niche players and integrates them onto its operational excellence platform, scaling EIG to $4,919.10M revenue and EMG to $2,482.02M revenue with minimal corporate overhead.Moderate
Post-acquisition integration friction and tariff absorption challenges from large-scale transactions
medium
12 to 18 months
Established integration framework under the AMETEK Growth Model, deployment of operational excellence toolkits, and proactive contractual price escalation mechanisms.5
Synchronized industrial contraction across European and Asian manufacturing end markets
high
6 to 12 months
Geographic diversification with US generating $3,830.64M, Asia $1,488.79M, and EU $1,089.53M, paired with an asset-light flexible cost structure.5,8
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Revenue expands solidly in FY2026 and accelerates in FY2027 as Indicor is fully integrated, before moderating steadily across FY2028, FY2029, and FY2030 toward long-term trend rates.
Operating margin progresses steadily from FY2025 through FY2026, FY2027, FY2028, FY2029, and FY2030, supported by continuous operational excellence initiatives and pricing discipline.
Diluted EPS compounds steadily from FY2026 through FY2030, driven by operating earnings expansion and ongoing deleveraging.
Reinvestment rate remains low and disciplined as a percentage of NOPAT, supporting an asset-light capital expenditure run rate relative to sales.
Effective tax rate holds steady for FY2026 and FY2027 before normalizing through FY2030.
Terminal perpetual growth aligns with long-term macroeconomic expansion alongside a terminal exit multiple aligned with peer medians.
The base case represents the modal expected compounding path under the approved house schedule. AMETEK delivers solid revenue growth in FY2026 and FY2027 as Indicor's sales contribution is absorbed, with organic growth subsequently moderating toward a sustainable long-term trajectory. Operating margins expand steadily from FY2025 through FY2026 and FY2027, reaching peak efficiency by FY2030. Disciplined reinvestment relative to NOPAT and an exit multiple bridge toward peer medians yields the committee fair value of $171.80.
Revenue growth compounds at an accelerated pace through FY2028, supported by rapid Indicor revenue synergy capture and robust commercial aerospace delivery rates.
Operating margins expand substantially from FY2025 levels through FY2028, driven by a high-margin recurring consumables mix in Indicor and operational excellence lean initiatives.
Free cash flow conversion exceeds net income sustainably, allowing complete retirement of acquisition-related short-term commercial paper borrowings ahead of schedule.
Effective operating tax rate normalizes and capital expenditures remain contained as a modest percentage of sales.
Under the bull case, rapid synergy realization from Indicor Instrumentation accelerates revenue and margin expansion, while sustained secular demand across aerospace, semiconductors, and power grid infrastructure drives organic growth well above historical trend. Full-year sales growth reaches high levels through FY2027, and operating margins expand past prior cyclical peaks as core instrumentation pricing power consistently overcomes tariff friction. Strong free cash flow enables rapid post-acquisition deleveraging, supporting premium multiple valuation parity with high-performing peers.
Trigger: Adjusted diluted EPS and organic sales growth tracking within management guidance ranges in Q3 and full-year FY2026 with stable book-to-bill metrics.
Results meeting management guidance confirm steady operational execution but leave the shares vulnerable to multiple de-rating given the substantial premium over intrinsic fair value.
Miss
Maintain Sell; Immediately execute full portfolio liquidation and remove all exposure, auditing organic revenue trends across European and Asian end markets for structural deterioration.
Trigger: Adjusted diluted EPS falling short of guidance in Q3 and full-year FY2026 or organic sales growth decelerating due to European industrial stagnation or tariff cost absorption.
An earnings miss would demonstrate that input tariffs, Indicor integration friction, or European industrial stagnation are eroding core profitability, accelerating valuation multiple contraction toward peer medians.
Earnings quality is high and transparent. Non-GAAP adjustments are consistently clean across reporting periods, primarily comprising pretax amortization of acquisition-related intangible assets and discrete acquisition integration costs. Operating cash flow in FY2025 comfortably supported operating income after adjusting for non-cash depreciation and amortization, and sustained free cash flow conversion demonstrates that reported adjusted earnings convert reliably into realized cash.6
Metrics to watch into the print
01
Metric:
Indicor Instrumentation Integration and Margin Accretion
CurrentAcquisition closed in late Q3; integration teams actively executing onboarding.
Why it matters
The acquisition is AMETEK's largest ever; delivering the expected full-year sales contribution and scaling recurring consumables revenue is essential to justify capital outlay.5
02
Metric:
Organic Sales Growth Rate across EIG and EMG
CurrentAccelerated from Q1 into Q2 2026 with robust order growth and a positive book-to-bill across both operating groups.
Why it matters
Distinguishes true underlying end-market demand from acquisition-driven revenue expansion, particularly across European and Asian industrial markets.8
AMETEK's cash-generative compounding engine is among the strongest in the industrial sector. In FY2025, operating activities generated $1,801.76M in cash flow, which after deducting $130.25M of capital expenditures produced $1,671.52M in free cash flow. Working capital management is highly disciplined, supported by negative working capital dynamics in select custom instrument contracts. Stock-based compensation of $47.77M in FY2025 represents just 0.65% of sales, well below the 0.9% industry average, highlighting minimal cash dilution. Cash flow generation accelerated in Q2 2026, with operating cash flow rising 35% YoY to $483.69M and FCF reaching $451.68M after $32.01M in CapEx. With FY2026 full-year CapEx guided to ~$160M, projected free cash flow provides substantial internal liquidity to rapidly deleverage following large-scale capital deployments.5,6,7
AMETEK's capital allocation philosophy is centered on programmatic, value-accretive M&A governed by the AMETEK Growth Model. In August 2026, the company completed its largest transaction to date, acquiring Indicor Instrumentation for $5.0B in all-cash consideration. To support acquisition financing and working capital flexibility, AMETEK expanded its unsecured commercial paper program from $2.3B to $3.5B. Prior to this closing, reported total debt stood at $2,310.94M as of October 2026 against a pre-tax cost of debt of 5.78% and debt-to-capital weight of 3.85%. Dividend distributions remain modest and well-covered, with a base rate of $1.36 per share annually (representing ~21% of FY2025 GAAP EPS of $6.40), preserving the overwhelming majority of cash flow for debt retirement and tuck-in acquisitions.
AMETEK's underlying economic profitability is exceptionally healthy, though reported accounting ROIC is mechanically dampened by accumulated goodwill and intangible assets totaling over $12.2B ($7,418.30M goodwill and $4,840.13M other intangibles as of Q2 2026) from programmatic M&A. On a tangible capital basis, cash returns on capital are substantially higher, as physical capex represents only ~2% of sales ($130.25M in FY2025) and operations generate over $1.67B in annual free cash flow. The completed $5.0B Indicor transaction expands invested capital in the near term, but high free cash flow conversion of 111% ensures rapid economic capital recovery.
Reported ROIC of 11.73% generates a solid positive economic spread over the computed WACC of 9.0619%, backed by robust GAAP operating margins of 25.81%.
AMETEK generated FY2025 GAAP operating income of $1,910.32M on revenue of $7,401.12M, yielding an operating margin of 25.81%, compared to the peer industry benchmark of 16.1%. EIG delivered an operating margin of 29.42% ($1,447.06M EBIT on $4,919.10M revenue), while EMG delivered 23.33% ($578.94M EBIT on $2,482.02M revenue).
Exceptional margin quality confirms deep pricing power in niche instrumentation, providing a substantial earnings cushion against raw material inflation and cyclical volume downturns.
In FY2025, operating cash flow reached $1,801.76M and CapEx was $130.25M, yielding free cash flow of $1,671.52M against GAAP net income of $1,480.14M —a conversion rate of 112.9%. In Q2 2026, non-GAAP free cash flow conversion stood at 111% ($451.68M FCF).
Superior cash generation funds programmatic M&A without requiring equity dilution, keeping shares outstanding flat to declining (231.26M diluted shares in FY2025 down to 229.20M basic shares as of 2026-10-04).
Asset-Light Operations Minimize Maintenance Capital Drag
AMETEK's capital intensity of 1.76% in FY2025 ($130.25M CapEx on $7,401.12M sales) and guidance of approximately $160M (~2.0% of sales) in FY2026 sits far below the peer industry average capex-to-revenue ratio of 4.1%.
Low physical asset reinvestment requirements enable over 80% of operating cash flow to be deployed dynamically into strategic acquisitions, debt paydown, or opportunistic capital returns.
AMETEK Inc. (AME) trades at 28.3x forward earnings against a peer median of 19.8x. Its EV/EBITDA of 23.8x compares with a peer median of 19.3x. The comparison uses 4 peers: Cummins Inc., Emerson Electric Co., Parker-Hannifin Corporation and Generac Holdings Inc., as of 2026-10-03 to 2026-10-04.
The bearish industrial cycle materializes when high real interest rates and geopolitical trade barriers stifle industrial fixed asset investments, leading to widespread channel destocking across European and Asian factory automation markets. Slower factory run-rates suppress orders for process instrumentation and test equipment, causing book-to-bill metrics to fall below parity. Under this environment, unabsorbed overhead and competitive discounting for new program awards compress operating margins toward the peer industry average of 16.1%, while capital-constrained industrial operators defer major instrumentation upgrades.
Secular trends
Trend
Impact
Note
Global Electrical Power Grid Expansion and Modernization
positive
Accelerating electrification, renewable energy integration, and AI data center power demand are driving multi-year investment cycles in grid infrastructure, resulting in strong orders momentum for AMETEK's power and process instrumentation businesses.
Semiconductor Fab Tool Expansion and Sub-2nm Lithography
positive
Advanced packaging, domestic chip onshoring, and rising process complexity require extreme precision measurement and thermal control, driving standout order growth in EIG's semiconductor product lines.
Commercial Aviation Fleet Replacement and Defense Readiness
positive
Elevated aerospace backlogs and defense budget growth across NATO allies support low double-digit order growth in Aerospace & Defense platforms, where AMETEK's components enjoy 20+ year platform life cycles.
Tariff Proliferation and Geopolitical Supply Chain Fragmentation
negative
Rising cross-border tariffs and protectionist policies increase supply chain friction, necessitating continuous pricing surcharges and local manufacturing realignments to preserve operating margins.
Positioning
AMETEK is strategically positioned as a premier supplier of critical, high-margin instrumentation across EIG ($4,919.10M sales) and EMG ($2,482.02M sales). By deliberately targeting niche markets where product specifications are stringent and substitution costs are high, AMETEK captures an operating margin of 25.81%, sharply outperforming the broader industry average of 16.1%. Its balanced geographic exposure across the United States ($3,830.64M), Asia ($1,488.79M), and Europe ($1,089.53M) enables the company to capitalize on regional capex surges while maintaining disciplined capital intensity.5,7,8
Entry tranches
Level
Action
Why
$171.80
Re-evaluate fundamental risk/reward profile for potential Hold rating revision
Corresponds to the house midpoint fair value, where the market multiple normalizes toward 19.3x forward earnings and eliminates the prevailing price premium.
Assess phased initial long position accumulation
Corresponds to the lower bound of the committee fair value range, establishing an adequate margin of safety against cyclical manufacturing risks and debt integration headwinds.
Exit tranches
Level
Action
$251.93+
Execute immediate and total liquidation of all outstanding long positions at prevailing market prices
$260.00
Utilize any temporary post-earnings momentum or liquidity spikes to accelerate complete portfolio exit
Audit working capital build and CapEx discipline to verify whether asset-light compounding model is deteriorating.
Cyclical Industrial Accounts
Avoid
Near-term cyclical momentum is vulnerable to deceleration across European ($1,089.53M) and Asian ($1,488.79M) markets. The debt-financed $5.0B Indicor transaction increases balance sheet leverage, creating heightened sensitivity to interest costs and multiple de-rating.5,8
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Discounted forecast-period cash flows ($32.70) plus discounted terminal value ($117) minus signed net debt per current share ($7.96) equals the $141 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
